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Abstract
Background: Adults with co-occurring mental and substance use disorders (CODs) are overrepresented in jails.
In-custody barriers to treatment, including a lack of evidence-based treatment options and the often short periods
of incarceration, and limited communication between jails and community-based treatment agencies that can
hinder immediate enrollment into community care once released have contributed to a cycle of limited treatment
engagement, unaddressed criminogenic risks, and (re)arrest among this vulnerable and high-risk population. This
paper describes a study that will develop research and communication protocols and adapt two evidence-based
treatments, dual-diagnosis motivational interviewing (DDMI) and integrated group therapy (IGT), for delivery to
adults with CODs across a jail-to-community treatment continuum.
Methods/design: Adaptations to DDMI and IGT were guided by the Risk-Need-Responsivity model and the National
Institute of Corrections’ implementation competencies; the development of the implementation framework and
communication protocols were guided by the Evidence-Based Interagency Implementation Model for community
corrections and the Inter-organizational Relationship model, respectively. Implementation and evaluation of the
protocols and adapted interventions will occur via an open trial and a pilot randomized trial. The clinical intervention
consists of two in-jail DDMI sessions and 12 in-community IGT sessions. Twelve adults with CODs and four clinicians
will participate in the open trial to evaluate the acceptability and feasibility of, and fidelity to, the interventions and
research and communication protocols. The pilot controlled trial will be conducted with 60 inmates who will be
randomized to either DDMI-IGT or treatment as usual. A baseline assessment will be conducted in jail, and four
community-based assessments will be conducted during a 6-month follow-up period. Implementation, clinical,
public health, and treatment preference outcomes will be evaluated.
Discussion: Findings have the potential to improve both jail- and community-based treatment services for adults
with CODs as well as inform methods for conducting rigorous pilot implementation and evaluation research in
correctional settings and as inmates re-enter the community. Findings will contribute to a growing area of work
focused on interrupting the cycle of limited treatment engagement, unaddressed criminogenic risks, and (re)
arrest among adults with CODs.
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Background
More than two million adults with serious mental ill-
nesses (SMIs), including schizophrenia-spectrum, bipo-
lar, or major depressive disorders, are admitted to US
jails annually [1]. A majority of justice-involved adults
with SMI also have alcohol or drug use problems. Sub-
stance use among adults with SMI is a complicating
treatment factor, as drug and alcohol use worsens illness
trajectories [2–4], increases the cost of treatment [5],
and is associated with multiple negative outcomes, in-
cluding homelessness, arrest, and violence [6–8]. How-
ever, there are many jail-based barriers to treatment for
co-occurring mental and substance use disorders
(CODs), including a lack of evidence-based treatment
options and the often short periods of incarceration.
There also is limited communication between jails and
community-based treatment agencies, which decreases
the likelihood of immediate entry into community care
upon release. As a result, justice-involved adults with
CODs experience high rates of treatment failure, and
jail-based and community-based services struggle to
intervene effectively. Together, these issues have contrib-
uted to a cycle of limited treatment engagement, unad-
dressed criminogenic risks, and (re)arrest among this
vulnerable and high-risk population [9–11].
Although evidence-based programs for CODs are
available for inpatient and outpatient settings [2, 5,
10, 12, 13], effective treatment programs for justice-
involved adults with CODs are limited [4, 6, 14–16].
Despite an inmate’s constitutional right to adequate
healthcare [17], behavioral health treatment in jail is
rarely evidence-based or focused on key leverage
points, such as community re-entry or criminogenic
risks. Several factors have contributed to this lack of
evidence-based care, including jails’ limited capacity
to respond to inmates’ behavioral health needs, the
long-standing mission of incapacitation and punish-
ment rather than rehabilitation, and the often short
periods of incarceration and frequently unknown re-
lease dates for inmates, which limits the opportunities
for and duration of in-jail treatment when available. Also,
frequent and ongoing coordination with community-
based agencies regarding inmates’ immediate enrollment
in community services upon release from jail remains a
challenge [18].
The issues are as follows: (1) Can existing evidence-
based practices be adapted and delivered to justice-
involved adults with CODs across both jail and com-
munity settings in a way that mitigates these barriers
while also reducing re-arrest, substance use, and psy-
chiatric symptoms and improving quality of life? (2)
Can communication protocols be developed that fa-
cilitate immediate entry into community-based ser-
vices upon release from jail? If so, what are the
available and effective interventions that are portable
to the jail setting and amenable to the inclusion of
criminogenic risks? In addition to existing guidelines
and recommendations for jail-based services [18, 19],
the mental health services literature describes several
strategies that focus on organizational and clinical
changes and the development of effective intra- and
inter-agency communication that improves outcomes
associated with transitions from institutional to com-
munity care [20–24]. These include discharge planning,
information sharing, monitoring of clients post-release,
immediate and intensive community-based care, and peer
support workers who span both the institutional and com-
munity settings. Still, the development and adoption of
and adherence to guidelines, recommendations, and
improvement interventions for clinical care with justice-
involved adults with CODs have proven difficult in both
the jail setting and during the transition to the
community.
Objectives
The objectives of the current study are to (1) develop re-
search protocols to obtain access to a jail population, imple-
ment a rigorous research design, including randomization
to a pilot trial, and ensure that participants do not perceive
any undue coercion to participate; (2) develop communica-
tion protocols so that jail and community treatment are co-
ordinated and linked for effective community re-entry; and
(3) adapt the clinical content of extant evidence-based pro-
grams to better address both behavioral health and crim-
inogenic needs of jail inmates with CODs, including anger
management, harm reduction, illness management, crim-
inal thinking, antisocial peer networks, and treatment mo-
tivation. The following research aims were designed to
address these objectives:
 Aim 1: To adapt evidence-based interventions for
delivery to jail inmates as they transition from
institutional to community living, examining the
initial acceptability of the adaptations through an
uncontrolled open trial
 Aim 2: To conduct a pilot randomized controlled
trial (RCT) to establish knowledge in three priority
areas:
Aim 2.1: The feasibility and acceptability of the
adapted interventions
Aim 2.2: The feasibility and acceptability of the
proposed research and communication protocols
Aim 2.3: The effectiveness of and estimated effect
sizes associated with the adapted interventions
vis-à-vis reductions in re-arrest, substance use,
and psychiatric symptoms, and improvements in
uptake of usual care.
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Methods/design
This project was developed in partnership with multiple
community organizations, including the county’s man-
aged care organization, multiple community-based pro-
vider agencies, and the county jail. Each of these
partners helped shape the proposal, including the devel-
opment of the communication and research protocols
and the selection of the treatments to be adapted. The
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist is included as Add-
itional file 1, and the SPIRIT figure for the RCT is
presented in Fig. 1. The study flowchart is provided in
Fig. 2.
Interventions
Dual-diagnosis motivational interviewing (DDMI) [25–
27] and integrated group therapy (IGT) [28–31] are two
integrated dual disorder treatment (IDDT) programs
with strong evidence bases. IDDT programs are the
“standard of evidence-based treatment” for adults with
CODs ([32], p. 317). After a review of multiple IDDT
and non-IDDT treatment programs, our partner agen-
cies believed DDMI and IGT to be appropriate candi-
dates for adaptation to justice-involved populations.
Dual-diagnosis motivational interviewing
DDMI is an adaptation of motivational interviewing [26]
that incorporates an integrated framework and accom-
modates the cognitive impairments and disordered
thinking associated with CODs. For example, DDMI in-
cludes simplified open-ended questions, refined reflect-
ive listening skills, and integration of psychiatric issues
into personalized feedback and decision making. Given
its portability and effectiveness in few sessions [27],
DDMI was thought to fit particularly well within the
context of brief, but intensive jail-based treatment prior
to community re-entry. In the current study, DDMI ses-
sions lasting approximately 60 minutes will be delivered
one on one to inmates in the jail prior to their first court
appearance. When possible, inmates will receive a sec-
ond DDMI session before anticipated release from jail.
Integrated group therapy
IGT is an evidence-based practice that has been cited by
the National Institutes of Health (NIH) as one of five ex-
amples of “promising behavioral therapies” for adults
with CODs ([33], p. 3). IGT uses cognitive and behav-
ioral strategies to address substance use, psychiatric
symptoms, and medication nonadherence via a focus on
(1) promoting abstinence from drugs, including alcohol;
Fig. 1 Pilot RCT enrollment, interventions, and assessments according to SPIRIT guidelines
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(2) promoting adherence to psychiatric medications; (3)
teaching mood- and thought-monitoring skills; (4) teach-
ing social skills; and (5) improving other aspects of life
functioning [30]. Because cognitive-behavioral therapies
like IGT are effective for treating adults with CODs [34,
35], including the reduction of antisocial behaviors [36,
37], our partners believed that community-based IGT
also was an appropriate treatment to adapt for the jail-
to-community treatment continuum. The goal is to have
inmates, within 1 week of release from jail, enroll in IGT
and participate in 12 90-minute IGT sessions with four
to eight other inmates for 6 weeks. IGT sessions will be
run with an open enrollment format [30] to facilitate a
quick jail-to-community transition period and rapid en-
gagement in community-based treatment [9].
Conceptual frameworks
Our treatment adaptation and implementation and com-
munication protocol frameworks are described next.
Treatment adaptation framework
Our treatment adaptation framework is guided by the
Risk-Need-Responsivity (RNR) model [38, 39] and the
National Institute of Corrections’ (NIC’s) implementation
competencies [40]. Within RNR, the risk principle indicates
that individuals at highest risk of future adverse outcomes
should be identified and resources allocated accordingly.
The need principle asserts that interventions should target
criminogenic needs related directly to adverse outcomes for
the individual offender. The responsivity principle affirms
that strategies should be sensitive to identified risk and
needs, while being delivered in a way that considers individ-
ual factors that can affect treatment outcomes (e.g., learning
style). There are eight NIC implementation competencies
that also informed our treatment adaptation process: assess
risk and need, enhance motivation, target interventions,
cognitive-behavioral skill training, positive reinforcement,
increase ongoing support, measure processes and practices,
and measurement feedback.
Through the integration of RNR principles and NIC
competencies, DDMI will be adapted for in-jail use with
a focus on motivating the inmate for community re-
entry, continuity of care, and uptake of routine out-
patient services. IGT will be adapted for more intensive,
staged delivery of sessions that target criminogenic risk
and needs, while continuing to enhance motivation for
uptake of routine outpatient services.
Implementation framework
Our implementation framework is guided by the Evidence-
Based Interagency Implementation Model (EB-IIM) for
community corrections [40]. This framework considers
multiple, interacting levels at which implementation must
occur, including the role of inner and outer settings in
implementation. For example, we will focus on developing
knowledge and building a foundation through the open
trial (i.e., preparation phase), in addition to establishing
agreed-upon expectations for the jail and community part-
ners and aligning the jail’s policies and procedures to
accommodate changes identified through the two trials.
Finally, ongoing treatment adaptations, informed via open
trial results, should improve the likelihood of sustaining a
successful jail-to-community-based treatment continuum
through and then beyond the pilot RCT.
Communication framework
Our communication protocols will be based on the Inter-
organizational Relationship (IR) model that emphasizes
situational factors, as well as process, structural, and out-
come dimensions in inter- and intra-agency communica-
tion. The IR model defines the situational factors (e.g., need
for resources) and process (e.g., intensity of information
flow), structural (e.g., complexity), and outcome dimensions
(i.e., perceived effectiveness) necessary for inter-agency
collaboration. Thus, in addition to developing and testing
inter-agency communication protocols (e.g., from jail to
community treatment), we also will develop and test intra-
agency communication protocols (e.g., how to manage
Fig. 2 Pilot RCT study flowchart
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scheduling conflicts between IGT and usual care services).
The IR model has been used effectively across service set-
tings [41–44] and maps onto the technical, procedural, and
resource dimensions of the EB-IIM’s foundation core [40].
Study design
The study consists of two phases: (1) an uncontrolled
open trial and (2) a pilot RCT. During the open trial
phase, we will collect data to inform the refinement of the
research and communication protocols and the adapted
interventions—broadly, the jail-to-community treatment
continuum. For example, results from the uncontrolled
open trial may result in changes to the inmate participant
recruitment and consent process, procedures for facilitating
inter-agency communication, and additional adaptations to
the DDMI-IGT continuum training materials, manuals, or
session handouts. All modifications to the research and
communication protocols and to the adapted interventions
will be made in collaboration with community partners
throughout the uncontrolled open trial and implemented in
the pilot RCT.
Setting
The study will be conducted at a large urban county jail in
the southeastern USA. The jail’s average daily census ranges
between approximately 1300 and 1450 with one-quarter of
those inmates identified as being in need of mental health
evaluation beyond standard screening completed during
booking. Within 24–48 hours, on average, all inmates have
their first court appearance. From there, inmates are either
(1) bonded out or have their charges dropped or (2)
detained and sent to Misdemeanor or Felony Court. From
Misdemeanor or Felony Court, inmates are released or
sentenced.
Inmate participants
Inmate participants will be broadly representative of adults
with CODs in a large urban county jail. Twelve inmates will
be enrolled in the open trial and 60 in the pilot RCT. Eligi-
bility criteria are: 18 to 65 years of age; incarcerated in the
county jail; a resident of the county; able to speak and read
English; and meet Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) diagnostic criteria
for (1) drug or alcohol abuse or dependence and (2) a
serious mental illness, including major depressive disorder,
depressive disorder not otherwise specified (NOS), bipolar
disorder I, II, or NOS, schizophrenia-spectrum disorder,
schizoaffective disorder, schizophreniform disorder, brief
psychotic disorder, delusional disorder, or psychotic dis-
order NOS, based on review of clinical records and input
from available informants, including jail-based clinicians.
Community partner participants
Community partner participants will be clinicians working
in local behavioral healthcare agencies who will provide the
intervention to treatment participants. Clinicians (n = 4)
from a local behavioral health agency will be recruited and
trained to provide the treatment to participants. Two clini-
cians will provide DDMI treatment to participants in the
jail prior to release into the community. Two clinicians will
provide the IGT treatment to participants in the commu-
nity after release from jail. To be eligible, clinician partici-
pants must be providing clinical services to jail inmates
with co-occurring substance use and mental health disor-
ders, at least 18 years of age, able to speak/read English,
and able to provide informed consent.
Clinician training
Prior to the start of the open trial, we will provide 1 day of
training on IDDT principles, frameworks for treatment
adaptation and implementation, and the DDMI and IGT
programs to all study clinicians. We also will provide a
second day of training separately for the DDMI and IGT
clinicians, focusing on jail- and community setting-
specific issues relevant to each of the interventions. Clini-
cians will receive a booster training during the open trial
that will address modifications and refinements to DDMI
and IGT and the communication protocols, as informed
by open trial data. Clinicians will be retrained prior to the
start of the pilot RCT and will receive another booster ses-
sion midway through the RCT.
Participant identification and recruitment
Participants will be identified for potential participation
in the study through routine screening measures at
booking, including the Brief Jail Mental Health Screen
[45] and other jail-specific mental health and substance
use screening protocols. The Jail Mental Health Liaison
will identify participants who meet the study inclusion
criteria, which were noted above, and the jail-based clin-
ician will approach potential participants (after booking
but before the first court appearance) to inquire about
interest in study participation.
Uncontrolled open trial
Recruitment and participation in the open trial will
occur in two cycles to allow for evaluation and modifica-
tion of the DDMI-IGT treatment continuum, as neces-
sary. In the first cycle, six inmates will participate. The
adapted interventions and communication and research
protocols will be modified as necessary, based on inmate
and clinician feedback. After modifications, another six
inmates will participate in the second open trial cycle.
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Pilot randomized controlled trial
For the pilot RCT, all inmates who consent to participate
will be randomly assigned to one of two conditions: the
DDMI-IGT treatment group or the control group. After
consent, participants will receive their group assignment.
All inmates will be given a preassigned study ID, each asso-
ciated with assignment to either the treatment or control
group, as determined by a random number generator.
Participants will be informed of their allocation to study
condition by the research interviewer. Allocation is not
concealed, as participants will be asked to provide feedback
on their satisfaction with, and preferences for, treatment
(see Table 1).
Treatment group
Inmates assigned to the treatment group will participate in
the DDMI-IGT continuum. Between four and eight groups
of participants will complete the DDMI-IGT treatment
during the pilot RCT, depending on how many participants
are enrolled in each IGTcycle. No more than 8 inmates will
participate in IGT at any given time. In addition to the
DDMI-IGT treatment continuum, inmates in the treatment
condition also will receive any and all necessary usual care
across jail and community settings.
Control group
Inmates assigned to the control condition will receive
treatment as usual (TAU) and will not be enrolled in the
DDMI-IGT treatment continuum. That is, inmates in the
control group will continue to receive any and all usual
care services across jail and community settings, as do any
inmates regardless of participation in this study.
As noted, participants across both conditions will
receive any and all clinically indicated usual care services
across the jail and community sites. The delivery of those
services, including their discontinuation or modification if
needed, will be based on the treating clinician’s judgement
and appropriate treatment planning within the context of
the jail and community-based treatment system support-
ing the implementation of this project.
Assessment schedule and measures
Open trial
To address Aim 1, we will collect qualitative and quantita-
tive data regarding acceptability of, fidelity to, and feasibility
of the treatment from inmates and clinicians during the
uncontrolled open trial (see Table 1). Acceptability will be
evaluated to determine participant and clinician satisfaction
with the communication protocols and the DDMI-IGT
treatment continuum, using the Client Satisfaction
Questionnaire-8 (CSQ-8) [46, 47], Narrative Evaluation of
Intervention Interview (NEII) [48], semi-structured inter-
views, focus groups, and administrative records. Fidelity will
be examined at the end of the open trial to determine the
degree to which clinicians adhered to the adapted treat-
ment programs based on a review of audio recorded
treatment sessions and DDMI (Moyers, Martin, Manuel,
Miller, Ernst. Revised global scales:motivational interview-
ing treatment integrity 3.1. 1 (MITI 3.1. 1). Unpublished.)
and IGT [28] Adherence Forms. Feasibility will be evalu-
ated to determine the success of treatment implementation,
enrollment, and coordination, as well as the feasibility of re-
search and communication protocols, using data collected
from semi-structured interviews, focus groups, and admin-
istrative records.
Pilot randomized controlled trial
To address Aim 2, we will collect inmate and community
partner outcome data to evaluate treatment effectiveness,
feasibility, and acceptability of the pilot RCT (see Table 1).
Treatment effectiveness will be assessed using three
categories of outcome variables: (1) clinical, including
inmate substance use, psychiatric symptoms, health status,
service use, and quality of life; (2) criminal justice, includ-
ing contacts and re-arrest, which will serve as the primary
outcomes of the pilot RCT; and (3) treatment preferences.
These outcomes will be assessed five times, including
an in-jail baseline assessment and four additional
community-based assessments spanning 1 week to
5 months after jail discharge (see Table 1). In addition to
these effectiveness outcomes, we additionally will measure
implementation outcomes related to the interventions and
protocols. Specifically, feasibility and acceptability will be
assessed using the same measures from the open trial, in-
cluding inmate exit interviews, community partner focus
groups, and administrative record review. The primary
explanatory variable will be the experimental condition;
that is, whether participants were assigned to either the
treatment group (DDMI-IGT +TAU) or the control group
(TAU only). Additionally, we will collect sociodemo-
graphic data for participants, including diagnosis, race/
ethnicity, age, and sex, obtained through clinical and
administrative records. Inclusion of these variables will
allow examination of potential differences in treatment
outcome as a function of each variable while controlling
for sociodemographic factors in statistical analyses.
Analytic plan and statistical methods
Aim 1
We will conduct Aim 1 analyses to evaluate qualitative and
quantitative data regarding the feasibility of, fidelity to, and
acceptability of the DDMI-IGT continuum and protocols.
All transcribed qualitative data from interviews and focus
groups will be coded according to coding guidelines which
will concentrate on deductive themes focusing on the feasi-
bility and acceptability of treatment programs and proto-
cols. A subset of transcripts will be coded independently by
two team members in Atlas.ti using iterative content
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analysis [49]. Discrepancies will be resolved by refining
codes and definitions through team discussion, until >90%
agreement is reached. After all transcripts are coded, data
will be searched and data output analyzed to build an un-
derstanding of feasibility and acceptability and possible revi-
sions. For example, potential broad category codes could
include “feasibility challenges,” “feasibility facilitators,” and
“feasibility recommendations” with lower level codes indi-
cating data collected from providers and participants. Low-
level codes will be grouped into broader categories when
possible. Additionally, we will calculate and review descrip-
tive statistics of administrative data (e.g., call logs, frequency
of inter- and intra- communication, average number of
treatment sessions attended) to assess treatment and
Table 1 Uncontrolled open trial and pilot RCT measures and assessment schedule
Assessment schedule
Aim Construct Measure Measure characteristics Informant OT RCT
T0 T1 T2 T3 T4
1,
2.1,
2.2
Acceptability Client Satisfaction Questionnaire-8 (CSQ-8)
[49, 50]
8-item measure of satisfaction with
DDMI-IGT treatment continuum
Inmates X X
1,
2.1,
2.2
Acceptability Narrative Evaluation of Intervention
Interview (NEII) [51]
16-item interview for evaluating
interventions
Inmates X X
1,
2.1,
2.2
Acceptability, feasibility Focus groups Semi-structured groups about
satisfaction with treatment continuum
and protocols; implementation barriers,
impact on jail and agencies
Community
partners
X X
1 Fidelity DDMI Adherence Form [52] 10-item measure of adherence and
competence of DDMI sessions
Community
partners
X
1 Fidelity IGT Adherence Form [28] 15-item measure of adherence and
competence of IGT sessions
Community
partners
X
1,
2.1,
2.2
Feasibility Exit interviews Semi-structured interview of
treatment success, barriers
Inmates X X
1,
2.1,
2.2
Feasibility Administrative records Call logs; number of inter- and intra-
agency contacts
Community
partners
X X
1,
2.1,
2.2
Feasibility Service Tracking Form Treatment recruitment; sessions
attended in jail, session attending
in the community; graduation rates
Community
partners
X X
2.3 Effectiveness: clinical Addiction Severity Index (ASI) [53] 27-item measure of alcohol and
substance use in prior 30 days, or
since last assessment
Inmates X X X X X
2.3 Effectiveness: clinical Brief Psychiatric Rating Scale (BPRS)
[71]
18-item measure of psychiatric
symptom severity
Inmates X X X X X
2.3 Effectiveness: clinical Short Form Survey (SF-12) [72, 73] 12-item measure of health status
and impairment
Inmates X X X X X
2.3 Effectiveness: clinical Epidemiological Catchment Area
Interview [74]
14-item measure of self-reported
service and medication use
Inmates X X X X X
2.3 Effectiveness: clinical Triarchic Psychopathy Measure [75] 20-item disinhibition scale of
externalizing behaviors
Inmates X
2.3 Effectiveness: clinical Heinrichs-Carpenter Quality of Life
Scale, Plus [76]
31-item quality of life scale Inmates X X X X X
2.3 Effectiveness: public
health
Criminal Justice Records Electronic law enforcement records
of arrest; jail tracking of criminal
justice contacts
Community
partners
X
2.3 Effectiveness:
treatment
preference
CODs treatment preferences [77, 78] Visual analog ranking of preference
for 8 aspects of treatment
Inmates X
— Sample description Demographic information Diagnosis; age; race/ethnicity; sex Community
partners
X
OT uncontrolled open trial, RCT randomized controlled trial, T0 baseline assessment conducted in jail at treatment program enrollment, T1 within 1 week of jail
discharge, T2 3 weeks after jail discharge (mid-IGT treatment), T3 6 weeks after jail discharge (end of IGT treatment), T4 6 months after jail discharge
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protocol feasibility. Findings will be used to refine treat-
ment adaptations and protocols as needed prior to con-
ducting the pilot RCT.
Aim 2
We will examine baseline clinical, legal, and demographic
differences between groups to determine if RCT treatment
group randomization was successful [50]. Additionally, we
will assess demographic differences between consenters
and refusers, reasons for refusal, and retention rates.
To address Aims 2.1 and 2.2 regarding the feasibility and
acceptability of and fidelity to the treatment and protocols,
we will integrate qualitative and quantitative data by trans-
forming qualitative data (e.g., noting the occurrence of
themes in interviews and focus groups) to support or refute
quantitative results (i.e., data merging) [51–53]. All qualita-
tive data collected from inmates, clinicians, and jail
personnel will be analyzed using the coding approach de-
scribed above for Aim 1. Feasibility will be evidenced by the
acceptable rates of participant exposure (85% complete
DDMI; attend >1 IGT session/week) and retention (>75%
completion rate) in the treatment continuum [54–56].
Acceptability to clinicians will be evidenced by focus group
and interview themes reflecting an overall more positive
than negative perception (e.g., endorsement for continuing
the program, even if minor inconveniences are noted). Ac-
ceptability to inmates will be evidenced by average CSQ-8
item scores >3 [57] and interview themes reflecting more
positive than negative perceptions. Fidelity will be evi-
denced by mean item scores >4 (Moyers, Martin, Manuel,
Miller, Ernst. Revised global scales:motivational interview-
ing treatment integrity 3.1. 1 (MITI 3.1. 1). Unpublished)
for the DDMI and >3 [28] for the IGT fidelity ratings.
We will use a generalized linear mixed model (GLMM)
to address Aim 2.3 regarding the effectiveness of the
DDMI-IGT treatment condition. In addition to inferential
tests of significance and associated confidence intervals,
effect sizes will be estimated. Our approach will be ex-
tended to estimate standardized differences between the
means for planned contrasts in the amount of change that
has taken place between pairs of times. Effect sizes will be
ranked from highest to lowest, tabled, and graphed. Mind-
ful of concerns regarding estimation of effect sizes in pilot
studies and the accuracy of estimates of replication, our
goal will be to identify a consistent pattern in the results
that will help determine the choice of primary outcome
measures in future research [58, 59].
Although not a primary aim of this study, an important
clinical question is the extent to which the intervention
might be differentially effective as a function of inmate
characteristics at treatment entry. We believe four factors
might moderate intervention effectiveness and thus merit
attention in our future research: diagnosis or psychiatric se-
verity [8, 60]; substance use, including differential use of
alcohol or drugs [8, 61], psychiatric symptoms [61–63]; and
criminal [62, 63] or antisocial history, including disinhib-
ition [64]. Following our GLMM analyses, we will under-
take exploratory supplemental analyses by fitting expanded
statistical models that include these variables as additional
main effects and, more importantly, as interactions with
treatment condition, to assess the extent to which each
might moderate the treatment condition effect.
Monitoring
A Data Safety and Monitoring Board (DSMB), whose mem-
bers will be independent of the funding agency, the
National Institute on Drug Abuse (NIDA), will be brought
together to oversee the study’s activities and to ensure the
safety of human subjects, validity of findings, and need for
further data collection. The study principal investigator
(PI), Dr. Van Dorn, will interact with the DSMB at the
DSMB’s discretion (at least two meetings per year), provid-
ing them with material to review, monitor, evaluate, audit,
and make recommendations regarding: (1) protocols,
informed consent procedures, and safety plans; (2) study
progress (i.e., recruitment and retention, risk/benefit ratio
for subjects, adherence to timetable, quality of data); (3) the
impact of new treatment developments on the risk/benefit
ratio of the study; (4) continuation, modification, or termin-
ation of ongoing studies based on adverse events or benefi-
cial outcomes; (5) interim analyses; (6) confidentiality of
trial data and results of monitoring; and (7) procedures
likely to increase subjects’ burden, to raise ethical concerns,
or to give the appearance of a conflict of interest.
The PI will make the following available to the DSMB:
(1) all adverse events (RTI International protocol requires
the reporting, in writing, of all adverse events within 5 days
of the study team becoming aware of the adverse event. All
adverse event forms will be made available to the DSMB as
well as tables summarizing the occurrence of specific
events.); (2) all interim data analyses; (3) analyses requested
by the DSMB; and (4) all reports to NIDA and all publica-
tions. Finally, data management procedures, including
those for data entry and quality checks, coding, security,
and storage are available from the study PI.
Power analyses
The proposed study will have a small, but appropriate [65]
sample size of 60. This study is developmental in nature,
which informs how we have chosen to address the choice
of error rates and power to detect effects in our clinical and
public health outcomes. Prior research suggests small to
medium substance use and psychiatric symptom effects of
DDMI [25, 27] and IGT [28–30]. Therefore, type I error
rate α = 0.15 was chosen so as not to limit power to con-
duct inferential analyses, giving an 80% chance (1 – β = .80)
to detect a difference between the treatment conditions that
would explain 9% of the total variance [θ2 = .09] in an
Van Dorn et al. Trials  (2017) 18:365 Page 8 of 12
outcome variable if the null hypothesis were false (calcu-
lated using G*Power 3.1 [66]). This approach allows for
increased opportunity to detect a smaller effect, while run-
ning the risk that the effect will not replicate. This course
of action is appropriate for a developmental study and is
consistent with prior research involving adults with SMI
and preliminary-stage multivariable models [61].
Discussion
Adults with mental illness suffer disproportionately from
drug and alcohol problems and are overrepresented in
jails. Our study aims to address the problem of limited
treatment for this population. Therefore, we will adapt
DDMI and IGT for jail inmates with CODs and evaluate
the acceptability, feasibility, fidelity, and effectiveness of
implementing the adapted treatment continuum and as-
sociated research and communication protocols.
Innovation
Our study will advance current research and practice re-
garding evidence-based treatment for inmates with
CODs and associated research methodologies. We will
adapt two interventions, DDMI and IGT, for justice-
involved adults with CODs. Our project is grounded in
evidence-based conceptual and treatment processes and
will have the potential to improve substance use, psychi-
atric, arrest, and routine outpatient treatment uptake
outcomes among an underserved and high-risk popula-
tion. This type of research is needed to address the in-
creasing rates of persons with CODs in jail populations
and associated treatment failure. Second, the develop-
ment and implementation of RCT methodologies is
needed within and across jail and community settings to
demonstrate the feasibility, acceptability, and effective-
ness of adapting treatments and conducting RCTs with
this population. Accordingly, this study may influence
the progression of subsequent CODs and jail research
and encourage others to adopt similar rigorous and
system-bridging approaches.
Limitations
Our study has several limitations in the design and
implementation. Although court orders can be success-
ful in increasing treatment participation among adults
with CODs, substance use disorders (SUDs), and SMIs
[67–69], we do not propose any judicial oversight. This
decision is in line with the preferences of our commu-
nity partners and other ongoing studies [70] and has
proven to be successful in retaining participants. Given
our focus on one jail, the generalizability of our findings
may be limited; however, generalizability of our findings
can be examined in a future full-scale RCT. Allowing ac-
cess to TAU in both experimental conditions also pre-
sents several potential limitations. As much as possible,
our community agencies will have different clinicians de-
liver the DDMI-IGT and usual care services to experi-
mental and control participants; however, DDMI-IGT
and usual care will be provided in the same agencies,
which may result in treatment contamination. Fidelity
assessments will allow us to monitor DDMI-IGT treat-
ment integrity and to address this potential contamin-
ation. It also is likely that, across both experimental
conditions, inmates will receive different types and in-
tensities of usual care services, resulting in treatment
heterogeneity. This will not affect study interpretability,
however, because service intensity will be titrated to in-
dividual client needs, consistent with the RNR frame-
work [39]. If our DDMI-IGT continuum increases the
amount or duration of usual care service uptake, the ex-
tent to which improvements in outcomes can be “ex-
plained” by amount or duration of usual care services
could be explored by statistically controlling for these
services and comparing the treatment conditions, e.g.,
through analysis of covariance (ANCOVA) models.
Lastly, given that our study is focused on the preliminary
treatment adaptations and feasibility, we have not fo-
cused on differential effects of DDMI and IGT within
our treatment continuum.
Trial status
Participant recruitment for the RCT is ongoing.
Additional file
Additional file 1: SPIRIT checklist. Items addressed in the current clinical
trial. (DOC 123 kb)
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Disclosure of relevant information
Upon admission to the jail, if routine substance use and mental health
screening procedures indicate potential study eligibility, the jail clinician is
notified to approach the inmate to determine if he or she would be willing
to be approached by research staff to discuss participation in the study. If so,
then via the informed consent process, research staff will meet with the
inmate to explain the nature and purpose of the study, including standard
protections for human subjects, risks and benefits, and study procedures.
Potential participants are provided with a verbal overview of the content of
the study and then are asked to read through the consent form with a
member of the research team, including being asked to read aloud the
initial paragraph of the consent form to confirm literacy.
Assessment of comprehension
In addition to being asked to read aloud the first paragraph of the consent
form, potential inmate participants complete the University of California, San
Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire, which
is designed to assess understanding and appreciation of the information
concerning a research protocol among potential subjects with SMI. Also, should
a member of the research team have concerns regarding participants’ cognitive
impairments at any point during the consent process or data collection
activities, including in-custody and out-of-custody settings, the Mini-Mental
State Examination will be administered and scored immediately. Inmates
with cognitive impairments sufficient to prevent them from attending to,
understanding, or participating meaningfully in study procedures are
excluded from study participation.
Voluntariness
Potential participants will be asked about the presence of several potential
coercive influences (e.g., jail staff, other inmates) and then questioned
regarding degree of perceived coercion for each. Though perception of
coercion may be inaccurate (i.e., wrongly anticipating that the staff will
sanction nonparticipation), potential participants who perceive greater than
minimal risk will be excluded from the study.
Finally, inmates will be provided with an opportunity to receive answers to
any questions they might have concerning their participation. After completing
this three-step consent process, potential participants will be provided with a
copy of the consent form for their own records.
Clinician participants
For clinicians, written informed consent will be obtained prior to participation
in each focus group and qualitative interview. A member of the research team
will review the nature and purpose of the focus group/qualitative interview,
including standard protections for human subjects, risks and benefits, and focus
group procedures. Participants will be informed that the group/interview will
be audio recorded for transcription purposes. Following verbal overview of the
content of the study consent form, clinician, jail, and community correction
participants will read through the consent form. They also will be provided with
an opportunity to ask any questions they might have concerning participation.
Finally, they will provide written informed consent.
Certificate of confidentiality
We have obtained a US Public Health Service Certificate of Confidentiality.
This certificate indicates that research staff cannot be compelled to identify
study participants or reveal their data to government agencies. Participants
will be informed of this certification and receive an explanation regarding
the confidentiality of study data.
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